Timothy Doyle, MD
Cardiovascular Disease · Willoughby, OHNPI 1861451403
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Medtronic at 32.3% of the total. Reporting peaked in 2019 at $184 and has fallen 57.6% since, to $78 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in OH, where the typical reported total is $1,347.
Across 22 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$138
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$93
- Johnson & Johnson$68
- Novartis$66
- AstraZeneca$25
- Amgen$21
- plus $18 from 1 others
Across 23 payments — averaging $14,192 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$308K
- AstraZeneca$18K
What the payments were for
- Food & beverage$41597%
- Education$143%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 2 | $138 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $93 |
| Johnson & Johnson | 3 | $68 |
| Novartis | 5 | $66 |
| AstraZeneca | 2 | $25 |
| Amgen | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$126
How this compares
$429 in reported general payments places this provider in the 30th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 485 | $511,598 |
| XareltoRivaroxaban | 142 | $148,541 |
| EntrestoSacubitril/Valsartan | 35 | $47,434 |
| Repatha SureclickEvolocumab | 33 | $24,256 |
| FarxigaDapagliflozin Propanediol | 26 | $20,416 |
| Praluent PenAlirocumab | 11 | $7,942 |
| Metoprolol Succinate | 432 | $4,868 |
| Atorvastatin Calcium | 486 | $4,275 |
| Ranolazine ErRanolazine | 31 | $3,263 |
| Amlodipine Besylate | 666 | $3,010 |
| Lisinopril | 401 | $2,969 |
| Metoprolol Tartrate | 405 | $2,407 |
| Amiodarone Hcl | 56 | $2,353 |
| Midodrine Hcl | 51 | $2,258 |
| Ezetimibe | 58 | $2,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $68 | $148,541142 claims |
| NovartisEntresto | $66 | $47,43435 claims |
| AstraZenecaFarxiga | $25 | $20,41626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Willoughby
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
- Jayanta MukherjeeColumbus$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.